Combination of [68Ga]Ga-PSMA PET/CT and [18F]FDG PET/CT in demonstrating dedifferentiation in castration-resistant prostate cancer |
| |
| Institution: | 1. Department of Nuclear Medicine, Saglik Bilimleri University Diyarbak?r Gazi Ya?argil Research and Training Hospital, Diyarbakir, Turkey;2. Division of Medical Oncology, Department of Internal Medicine, Saglik Bilimleri University Diyarbak?r Gazi Ya?argil Research and Training Hospital, Diyarbakir, Turkey;3. Department of Nuclear Medicine, Saglik Bilimleri University Dr. Suat Seren Chest Diseases and Surgery Hospital, ?zmir, Turkey;4. Department of Nuclear Medicine, Dicle University Faculty of Medicine, Diyarbakir, Turkey;1. Clinique du Val d’Or, CIMEN Scintigraphie, 14, rue Pasteur, 92210 Saint-Cloud, France;2. Centre cardiologique du Nord, médecine et imagerie nucléaire, 32–36, rue des Moulins-Gémeaux, 93200 Saint-Denis, France;3. Hôpital Augustin-Morvan, médecine nucléaire, 3, avenue Foch, 29269 Brest cedex, France;4. Hôpital Huriez, médecine nucléaire, rue Michel-Polonovski, 59037 Lille, France;5. Centre Jean-Perrin, médecine nucléaire, 58, rue Montalembert, 63011 Clermont-Ferrand, France;6. Hôpital Bichat, médecine nucléaire, 46, rue Henri-Huchard, 75018 Paris, France;7. Hôpitaux universitaires Paris-Sud Bicêtre, médecine nucléaire, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France;8. Service de Biophysique et Médecine Nucléaire-Imagerie Moléculaire, Hôpitaux Universitaires Paris Saclay, AP-HP, CHU Bicêtre;1. Service de médecine nucléaire, groupe hospitalier Pitié-Salpétrière, 47–82, boulevard de l’Hôpital, 75651 Paris cedex 1, France;2. Service de médecine nucléaire, hôpital Bichat, 46, rue Henri-Huchard, 75018 Paris, France;3. Service de médecine nucléaire, hôpitaux universitaires Paris-Sud Bicêtre, 78, rue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France;1. Department of Pharmacology, SRM College of Pharmacy, SRM Institute of science and technology, Chennai, Tamil Nadu, India;2. Department of General Medicine, E.S.I. Hospital, Medavakkam Tank Road, 600023 Ayanavaram Chennai, Tamil Nadu, India;3. Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies (VISTAS), 600117 Pallavaram, Chennai, India |
| |
| Abstract: | Aim of the studyIn this study, we aimed to determine the factors affecting increased glucose metabolism, which is one of the dedifferentiation mechanisms, by using 18F]FDG and 68Ga]Ga-PSMA PET/CT in patients with castration-resistant prostate cancer (CRPC).Materials and methodNinety-three patients with CRPC were included in the study. Gleason score (GS), and total PSA and free PSA levels of the patients were recorded. Patient- and organ-based evaluations were performed according to the lesion uptakes as follows: score 0: PSMA (-) FDG (-), score 1: PSMA (+) FDG (-), score 2: PSMA (+) FDG (+) (FDG < PSMA), score 3: PSMA (+) FDG (+) (FDG = PSMA), score 4: PSMA (+) FDG (+) (FDG > PSMA), and score 5: PSMA (-) FDG (+). scores 1 and 2 were classified as group 1, and scores 3 to 5 were classified as group 2.ResultsThe median age of our patients was 70 (51–88) years. Eighty-eight patients (94.6%) were PSMA-positive, 78 patients (83.8%) were FDG-positive, and 89 patients (95.6%) were or PSMA or FDG positive. When the two groups were compared in terms of patient-based parameters, the median age and GS were found to be significantly higher in group 2. ROC analyses revealed that age and GS were significant in predicting group 2.ConclusionSince glucose metabolism can increase in CRPC patients with advanced age and high GS, we recommend combining 18F]FDG PET/CT with 68Ga]Ga-PSMA PET/CT in routine clinical practice in order to identify this patient subset and refer them to additional therapies. |
| |
| Keywords: | PSMA PET/CT Prostate cancer Castration resistance Glucose metabolism PSMA TEP-TDM Adénocarinome de la prostate Résistance à la castration Métabolisme du glucose |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
